ReviewCureus2025
Chimeric Antigen Receptor (CAR) T Cell Therapy for Neuromuscular Disorders: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Case reports and case studies increasingly demonstrate that chimeric antigen receptor (CAR) T cell therapy (CTCT) is beneficial not only in hematologic malignancies but also in immunologic diseases, including neuromuscular disorders. The aim of this review is to provide an overview of the current status of CTCT in immune-mediated neuromuscular disorders. This is a systematic review of relevant literature recruited using PubMed, Embase, Scopus, and Google Scholar search terms. Neuromuscular disorders for which CTCT has been used to date include myasthenia gravis (n = 4), Lambert-Eaton syndrome (n = 1), myasthenia/Lambert-Eaton overlap (n = 2), dermatomyositis (n = 2), immune-mediated necrotizing myositis (n = 2), idiopathic inflammatory myopathy (n = 1), anti-synthetase syndrome (n = 4), and chronic inflammatory demyelinating polyneuropathy (n = 2). In most cases, CTCT was directed against CD19-positive lymphocytes and in some cases against B cell maturation antigen. In all reported patients, there was a significant improvement in motor function and quality of life, with some even making a full recovery several months after the application of CTCT. In conclusion, CTCT appears to be a promising therapeutic option for patients with severe immune neuromuscular disorders in whom previous treatment with multiple immunomodulatory therapies has been ineffective. CTCT should be considered in patients with immune neuromyopathy who do not respond to immunomodulatory therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.